New
HealthMore in Health→
Evolocumab Trial Links LDL Lowering to Lower Death Risk
Key Takeaways
- A prespecified VESALIUS-CV analysis tracked 12,257 high-risk adults for a median of 4.6 years.
- Patients receiving evolocumab plus standard therapy had 20% lower all-cause mortality than placebo recipients.
- Estimated five-year mortality was 7.9% with evolocumab versus 9.7% with placebo.
- Researchers also reported fewer cardiovascular and noncardiovascular deaths, with benefits emerging after about 1.5 years.
DE
DT Editorial Team··via medicalxpress.com